Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Maturity Onset Diabetes of the Young
100%
sodium glucose cotransporter-2 inhibitors
97%
Cohort Study
52%
Sodium Glucose Cotransporter 2 Inhibitor
48%
Congestive Heart Failure
45%
Dipeptidyl Peptidase IV Inhibitor
32%
Randomized Controlled Trial
24%
Antidiabetic Agent
24%
Antipsychotic
24%
Tramadol
24%
Acute Heart Failure
24%
Atopic Dermatitis
24%
Attention Deficit Disorder
24%
Enkephalinase Inhibitor
24%
Diuretics
24%
Angiotensin Receptor
24%
Cardiovascular Disease
24%
Autism
24%
Corticosteroid
24%
Adverse Event
19%
Lung Edema
12%
Adult Respiratory Distress Syndrome
12%
Respiratory Failure
12%
Pneumonia
12%
Comorbidity
6%
Diseases
6%
Cardiovascular Mortality
5%
Keyphrases
Type 2 Diabetic Patients
24%
National Cohort Study
24%
Meta-analysis
24%
Cardiovascular Safety
24%
Autism Spectrum Disorder
24%
Attention Deficit Hyperactivity Disorder
24%
Metformin
24%
Evogliptin
24%
Triple Therapy
24%
Antipsychotics
24%
Oral Safety
24%
Post-discharge Outcomes
24%
Tramadol Use
24%
Case-time-control Study
24%
Dual Therapy
24%
Sulfonylurea
12%
Dipeptidyl peptidase-4 (DPP-4)
9%
Myocardial Infarction
9%
Cardiovascular Risk Factors
9%
Cerebrovascular Accident
9%
Type 2 Diabetes Mellitus (T2DM)
6%
Heart Failure
6%
Individual Outcomes
6%
Routine Clinical Practice
6%
Risk Reduction
6%
Medicine and Dentistry
Patient with Type 2 Diabetes
24%
Cohort Analysis
24%
Evogliptin
24%
Glycon
24%
Cardiovascular System
24%
Sulfonylurea
12%
Congestive Heart Failure
9%
Dipeptidyl Peptidase-4 Inhibitor
9%
Myocardial Infarction
9%
Maturity Onset Diabetes of the Young
6%